Colossal Biosciences Shifts Scientific Strategy for De-Extinction

Based on verified reporting from May 2026, including the discovery headline from Zamin.uz and primary sources from Colossal Biosciences, the biotechnology company has not announced a full abandonment of its de-extinction ambitions as of May 4, 2026. However, the company has shifted its strategic focus toward genetic rescue, conservation, and applied biotechnology—prioritizing projects that directly benefit living species and ecosystems.

Here is the verified status of Colossal Biosciences as of May 2026:

Dallas-based Colossal Biosciences, known for its high-profile de-extinction projects like the woolly mammoth and dire wolf, has **expanded its mission beyond resurrection** to include broader conservation and genetic rescue initiatives. While the company continues to pursue de-extinction, its recent announcements emphasize **scalable conservation platforms**—such as the $100 million Colossal Foundation, which funds projects like toxin-resistant quolls, amphibian genetic rescue, and AI-driven wildlife monitoring.

The company’s April 2026 announcement about the African bluebuck—a recently extinct antelope—demonstrates its ongoing commitment to de-extinction, but it also signals a shift toward **applied conservation technologies**. According to Colossal’s official statements, the bluebuck project is part of a broader effort to develop **reproductive breakthroughs for endangered species** and create **BioVaults** to preserve genetic diversity for thousands of species.

From De-Extinction to Genetic Rescue

Colossal’s strategic pivot is reflected in its recent funding and partnerships. In May 2026, the company secured **$200 million in Series C funding**, bringing its valuation to **$10.2 billion**. This funding will support not only de-extinction projects but also **genetic rescue programs**—such as creating toxin-resistant quolls (a type of Australian carnivorous marsupial) and developing vaccines for endangered species.

Ben Lamm, Co-Founder and CEO of Colossal Biosciences, has stated in recent interviews that the company’s mission is evolving to address **both extinction and biodiversity loss** through technology. While de-extinction remains a long-term goal, the immediate focus is on **saving species at risk of extinction** and leveraging genetic tools to restore ecosystems.

Key Developments in 2026

• Bluebuck Project: Colossal announced in late April 2026 that it would attempt to revive the African bluebuck, an antelope hunted to extinction in 1800. This project is framed as a step toward broader conservation efforts for African megafauna.
• Colossal Foundation: The foundation’s funding doubled to $100 million in April 2026, supporting projects like amphibian genetic rescue, toxin-resistant quolls, and AI wildlife monitoring.
• Funding Growth: The company’s valuation surged to $10.2 billion following a $200 million Series C round, reflecting investor confidence in its dual focus on de-extinction and conservation.
• Global BioVault: Colossal is expanding its BioVault initiative to preserve the DNA of 10,000 species, ensuring genetic material is available for future conservation and de-extinction efforts.

While Colossal has not abandoned de-extinction entirely, its recent announcements suggest a **strategic emphasis on immediate conservation impact**. The company’s shift aligns with broader debates in the scientific community about whether de-extinction efforts should prioritize **resurrecting lost species** or **saving those on the brink of extinction**.

Scientific and Ethical Debates

Critics argue that de-extinction projects divert resources from saving endangered species, while supporters believe such efforts can **inspire conservation** and provide tools for genetic rescue. Colossal’s new approach attempts to address both perspectives by integrating de-extinction research with **real-world conservation applications**.

For now, Colossal remains committed to its flagship projects, including the woolly mammoth and dire wolf, but its expanded focus on **genetic rescue and applied conservation** suggests a more balanced strategy moving forward.

As of May 4, 2026, there is no official statement from Colossal indicating a complete abandonment of de-extinction. Instead, the company is **broadening its mission** to include both resurrection and rescue—reflecting a growing recognition that **saving species today is just as critical as reviving those lost to history**.

Sources:

• Colossal Biosciences official announcements (April–May 2026)
• CNN, BioSpace, and Dallas Innovates coverage (April 30–May 1, 2026)
• Colossal Foundation funding updates (April 2026)